VER Share PerformanceMore
|52 week high||49.750 18/07/16|
|52 week low||16.000 18/05/17|
|52 week change||-27.195 (-60.44%)|
|4 week volume||11,366,387 29/04/17|
Latest News« previous» nextMore
28/04/2017 - 07:00 RNS
RNS Number: 5935D Vernalis PLC 28 April 2017 TOTAL VOTING RIGHTS VERNALIS PLC (the "Company") 28 April 2017 Vernalis plc (LSE: VER) announces that the Company's total issued share capital at the date of this announcement is 526,386,480 ordinary shares of 1p each, with one voting right per share. There are no shares held in treasury. The total numbe...
26/04/2017 - 09:05 StockMarketWire
Vernalis and Servier announce the achievement of two research milestones and one clinical milestone in their oncology dr...
26/04/2017 - 07:00 RNS
RNS Number: 3244D Vernalis PLC 26 April 2017 Servier and Vernalis plc announce achievement of 3 milestones in their oncology drug discovery collaboration Two research milestones and one clinical milestone, triggering a total payment of 2 million to Vernalis 26 April 2017 - Servier and Vernalis plc are pleased to announce the achievement of two research milesto...
21/04/2017 - 15:20 StockMarketWire
Panmure Gordon today downgrades its investment rating on Vernalis PLC (LON:VER) to hold (from buy) and left its pri...
21/04/2017 - 15:10 StockMarketWire
Stifel today reaffirms its hold investment rating on Vernalis PLC (LON:VER) and cut its price target to 24p (from 29p).
21/04/2017 - 11:57 StockMarketWire
Weakness in pharmaceutical stocks AstraZeneca (AZN) and Hikma (HIK), as well as consumer goods giants Reckitt Benck...
21/04/2017 - 08:46 StockMarketWire
London shares are making minor gains in early deals with multi-commodity miners benefiting from rises in industrial m...
21/04/2017 - 07:22 StockMarketWire
Vernalis said a complete response letter (CRL) from the US FDA did not raise any concerns with the formulation or pharm...
|Dividend yield||0 %|
Equity Research (VER)
FDA has issued a complete response letter (CRL) to Vernalis’ CCP-07 NDA following its 20 April PDUFA date, outlining questions that need to be addressed in an NDA resubmission for potential FDA...
Investment into addressing barriers to higher Tuzistra XR prescribing is starting to translate into higher prescription (Rx) rates. Mid-way through the second season post launch, both Rx and sales...
FDA acceptance of the CCP-08 NDA (setting a 4 August 2017 PDUFA date) advances Vernalis towards its goal of building a speciality US franchise of extended release (ER) prescription-only (Rx) cough...
- 1 of 4
Latest discussion posts More
“ Just need to time the close now ! Lurking on these beautiful trending stocks you can bet is where you can find me ! Its all I look out for 24/7 !! Just need the time to ...”▼
“Just me and him then, anyone else? M”▼
“Wow these guys really believe this is a winner. Glad I bought in last week. M”▼
Codes & Symbols
|Symbols||VER, LSE:VER, VER.L, VER:LN, LON:VER, XLON:VER|